Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) EPS (Basic) (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed EPS (Basic) for 6 consecutive years, with -$0.13 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 80.0% to -$0.13 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.48, a 121.15% increase, with the full-year FY2024 number at -$1.16, up 63.29% from a year prior.
  • EPS (Basic) was -$0.13 for Q3 2025 at Inhibikase Therapeutics, down from -$0.11 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.87 in Q4 2024 to a low of -$1.1 in Q2 2022.
  • A 5-year average of -$0.41 and a median of -$0.23 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): crashed 444.44% in 2023, then surged 478.26% in 2024.
  • Inhibikase Therapeutics' EPS (Basic) stood at -$0.2 in 2021, then crashed by 410.0% to -$1.02 in 2022, then surged by 77.45% to -$0.23 in 2023, then soared by 478.26% to $0.87 in 2024, then crashed by 114.94% to -$0.13 in 2025.
  • Per Business Quant, the three most recent readings for IKT's EPS (Basic) are -$0.13 (Q3 2025), -$0.11 (Q2 2025), and -$0.15 (Q1 2025).